X

Xenon Pharmaceuticals

Clinical-stage neurological disorder therapeutics developer

Vice President, Clinical Development (Pain)

Full-Time
$412.6k - $433.2k/yr+ Target Bonus + Stock Options
Expert
MD
Remote in USA+2 moreMore locations: Boston, MA, USA | Needham, MA, USA
HybridBoston-based candidates must be on-site at least two days per week; travel up to 30% domestically and internationally.
Biology & Biotech

About the job

Requirements
  • An MD and experience in pain drug development.
  • At least 12 years of clinical experience in a pharmaceutical or biotechnology environment.
  • At least 5 years of experience as a drug development program lead and/or managing teams.
  • Strong drug development background, including experience filing Investigational New Drug applications and New Drug Applications and bringing novel therapeutics into clinical development.
  • Experience designing and executing pain clinical trials to demonstrate safety and efficacy.
  • Broad experience implementing and executing Phase 1 to Phase 3 clinical trial designs and interpreting clinical data.
  • Training in Good Clinical Practice and knowledge of the research process, protocol adherence, and accuracy in research data collection and documentation.
  • Understanding of clinical trial operations, biostatistics, and data management techniques.
  • Good understanding of clinical pharmacology principles.
  • Working knowledge of health authority regulations regarding evaluation and approval processes.
  • Ability to establish credibility and confidence inside and outside the company through scientific acumen and leadership skills, including executive presence.
  • Ability to work as both a leader and contributing member of a small team.
  • Adherence to high ethical standards.
  • Strong written and verbal communication skills.
  • Creative problem-solving skills.
  • Flexibility of thought and openness to new ideas.
  • Ability to motivate and maintain a positive work environment.
  • Strong team organization and delegation skills, ability to promote cooperation among staff, and ability to resolve conflicts constructively.
Responsibilities
  • Develop and propose clinical development strategy for all pain development programs in compliance with global regulatory standards and in collaboration with key functional areas, external vendors, and advisors.
  • Collaborate with Program Management to run efficient and productive drug development program teams across all pain drug development programs.
  • Provide scientific and drug development expertise to the cross-functional development team through due diligence of scientific literature and indication knowledge.
  • Monitor external research and regulatory environments and emerging study data to ensure clinical development plans remain appropriate.
  • Identify and build relationships with key opinion leaders to promote scientific discussions in accordance with engagement strategies and plans.
  • Assemble expert panels and lead the management and hosting of advisory boards and other scientific consultant meetings to advise on clinical development.
  • Establish and manage Data Safety Monitoring Boards in collaboration with Drug Safety and Pharmacovigilance, as required.
  • Oversee analysis of potential safety events within and across studies in collaboration with Drug Safety and Pharmacovigilance.
  • Participate in review and interpretation of clinical trial data and provide insight into the clinical relevance of trial results.
  • Provide scientific input to regulatory documents for submissions and discussions with health authorities.
  • Contribute to publication plans and clinical data communications in collaboration with Medical Affairs.
  • Present program strategic plans to the Executive Leadership Team and Board of Directors as programs execute.
  • Develop short- and long-term objectives for the function in accordance with company strategies and plans.
  • Plan and manage budget proposals and approved budgets according to company strategic and operating plans and Finance policies.
  • Recruit, lead, direct, develop, coach, and evaluate direct reports in accordance with Human Resource policies and practices.
  • Ensure company policies are understood and followed by direct reports.
  • Travel domestically and internationally as required, up to 30% of the time.
  • Perform other duties as assigned.

About the company

Xenon develops therapies for neurological disorders, especially epilepsy, in a clinical-stage biopharma setting, using research, partnerships, and licensing to move candidates toward commercialization. Its products are designed to act on neurological and genetic targets, with XEN007 in Phase 2 for treatment-resistant pediatric absence epilepsy illustrating its development pathway and reliance on clinical testing. The company differentiates itself by focusing on genetics-informed neurology and a pediatric, targeted epilepsy pipeline supported by collaborations rather than broad, one-size-fits-all approaches. The goal is to discover, develop, and eventually bring to patients therapies that address unmet neurological needs, advancing outcomes through a strong clinical pipeline and strategic partnerships.

Company Size

201-500

Company Stage

IPO

Headquarters

Burnaby, Canada

Founded

1996

Get referred to Xenon Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • X-TOLE2 and X-TOLE3 keep enrolling, preserving epilepsy approval momentum.
  • X-NOVA2 remains powered at 360 patients, with topline due Q1 2027.
  • Executives bought $1.68 million shares on September 18, 2026, signaling confidence.

What critics are saying

  • September 17 pause in MDD and bipolar trials exposes azetukalner neuropsychiatric toxicity.
  • Psychosis, aphasia, and ataxia can shrink psychiatry upside and trigger FDA labeling.
  • If FDA rejects azetukalner or requires studies, Xenon's single-asset thesis breaks.

What makes Xenon Pharmaceuticals unique

  • Azetukalner is a first-in-class KV7 opener spanning epilepsy and psychiatry.
  • September 17, 2026 NDA submission gives Xenon its first commercialization path.
  • $1.25 billion cash funds operations into 2029, reducing near-term dilution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Short-& Long-term Disability
  • Accidental Death & Dismemberment
  • Life Insurance
  • Employee Assistance Program
  • 401(k) Company Match
  • Stock Options
  • Tuition Reimbursement
  • Paid Vacation
  • Paid Sick Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Oct 1st, 2026
Xenon executives buy $1.68M in shares as epilepsy drug heads to FDA

Xenon Pharmaceuticals saw its top executives purchase $1.68 million in shares on Thursday. CEO Ian Mortimer bought 30,000 shares worth approximately $1.12 million, whilst CFO Thomas Kelly acquired 15,000 shares for nearly $560,000. The biotech company submitted its lead drug Azetukalner to the FDA last month for focal onset seizures treatment, following positive Phase 2b and Phase 3 trial results. Xenon temporarily paused new patient enrollment in psychiatry studies after observing neuropsychiatric side effects, though this doesn't affect its epilepsy programme. The clinical-stage company ended Q2 with approximately $1.25 billion in cash and investments, which management expects will fund operations into 2029.

GlobeNewswire
Sep 21st, 2026
Xenon to present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit.

Xenon to present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) - Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: * TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00-2:25 pm ET Details about the presentation, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent K[V] 7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K[V] 7 and Na[V] 1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner. For Media: Colleen Alabiso Senior Vice President, Corporate Affairs [email protected]

Yahoo Finance
Sep 20th, 2026
Xenon Pharmaceuticals shares drop 32% after pausing psychiatry trials despite positive epilepsy NDA filing

Xenon Pharmaceuticals' shares fell 32.2% after the company voluntarily paused new enrolment in its Phase 3 major depressive disorder and bipolar depression studies due to neuropsychiatric adverse events. The decision came on the same day Xenon submitted a New Drug Application to the US FDA for azetukalner in focal seizures. The NDA is supported by two randomised, double-blind, placebo-controlled trials showing statistically significant seizure reduction and a consistent safety profile across more than 1,500 patient-years of exposure. The pause in psychiatry trials does not directly affect the epilepsy NDA or ongoing Phase 3 seizure studies, which remain the main driver of the company's investment narrative.

Seeking Alpha
Sep 18th, 2026
Xenon downgraded at Deutsche Bank after pause in depression trials.

Xenon downgraded at Deutsche Bank after pause in depression trials. Xenon Pharmaceuticals (XENE) fell 30% to reach its lowest level since November after the company paused enrollment in Phase 3 depression trials for its lead asset, azetukalner, following safety concerns, leading to a downgrade at Deutsche Bank. Analyst David Hoang Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.

TradingView
Sep 18th, 2026
Xenon downgraded at Deutsche Bank after pause in depression trials.

Xenon downgraded at Deutsche Bank after pause in depression trials. Xenon Pharmaceuticals XENE fell 30% to reach its lowest level since November after the company paused enrollment in Phase 3 depression trials for its lead asset, azetukalner, following safety concerns, leading to a downgrade at Deutsche Bank. Analyst David Hoang downgraded the Canadian biotech to Hold from Buy after the company paused enrollments in multiple late-stage trials for azetukalner in major depressive disorder and bipolar depression in reaction to several neuropsychiatric adverse events, including psychosis. However, Xenon XENE management argued that the decision was a temporary measure taken as a precaution and there won't be an impact on ongoing epilepsy studies.The nature of the events, as well as their severity and frequency, were in line with the known safety and tolerability profile of the drug, the company added. Despite those remarks, Hoang said, "We disagree and believe this impairs the molecule's overall profile as a potential best-in-class drug that would become the go-to, branded antiseizure medication of choice in focal epilepsy." The analyst slashed his price target on XENE to $46 from $90 per share. However, Stifel, Baird, and RBC Capital Markets were among the firms to reaffirm their bullish ratings on the stock. While the surprising decision leads to uncertainty, "we're confident there's minimal readthrough to FOS," Stifel analyst Paul Matteis wrote with a Buy rating, according to Bloomberg. RBC Capital Markets analyst Brian Abrahams reiterated his Outperform rating yet trimmed his price target to $70 from $81, noting, "We believe the core value remains epilepsy and do not see any major risk to the filing timelines or commercial launch." Baird analyst Brian Skorney also sounded cautious, lowering his price target to $90 from $97 despite an outperforming rating. "We still think the MDD study is adequately powered into the 1Q topline, and we see low-rate psychosis as an AE neurologists are equipped to manage," Skorney added.Disclaimer Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.